various cell types including neurons. Mitochondrial Ca 2+ accumulation is mainly mediated by the mitochondrial Ca 2+ uniporter (MCU), but recent reports also indicate that mitochondrial Ca 2+ -influx mechanisms are regulated not only by MCU, but also by multiple channels/transporters.
We previously reported that ryanodine receptor (RyR), which is a one of the main Ca 2+ -release channels at endoplasmic/sarcoplasmic reticulum (SR/ER) in excitable cells, is expressed at the mitochondrial inner membrane (IMM) and serves as a part of the Ca 2+ uptake mechanism in cardiomyocytes. Although RyR is also expressed in neuronal cells and works as a Ca 2+ -release channel at ER, it has not been well investigated whether neuronal mitochondria possess RyR [7, 10, 24] . Mitochondrial Ca 2+ accumulation was first recognized as an important mechanism for the acceleration of oxidative phosphorylation and electron transport chain activity, which results in the stimulation of ATP synthesis [12] . In addition, mitochondrial dysfunction and the loss of cellular Ca 2+ homeostasis are frequently observed together in pathophysiological conditions such as neuronal excitotoxicity, apoptosis and neurodegenerative disorders [8] . However, the detailed mechanisms of how altered mitochondrial Ca 2+ handling and/or mitochondrial dysfunction affect these neurological pathogenesis are not yet fully understood.
Mitochondrial Ca 2+ influx was originally considered as a single transport mechanism through mitochondrial Ca 2+ uniporter (MCU) which can be inhibited by ruthenium red and lanthanides (see reviews [7, 24] ). However, the molecular identities responsible for mitochondrial Ca 2+ accumulation have remained an unsolved question until very recently.
Recently, several groups have discovered the molecular identity of MCU and its regulatory proteins and confirmed it as the main mitochondrial Ca 2+ uptake mechanism (see reviews [19, 24] ). Although in these studies MCU was confirmed as the most dominant Ca 2+ influx mechanism, previous studies have identified additional Ca 2+ uptake pathways, which display different physiological and pharmacological characteristics from MCU theory (see reviews [7, 24] ).
Among these studies, we reported that ryanodine receptor (RyR) is one of the mitochondrial Ca 2+ influx mechanisms in another excitable cell-type, cardiomyocytes, termed mRyR (mitochondrial RyR) [2, 3] (see also reviews [24, 25] [3, 23] .
Although RyR is expressed [9, 11, 31] 
Materials and Methods
An expanded Material and Methods section is available in the online supplementary file.
Reagents and antibodies
All reagents and antibodies were purchased from Sigma-Aldrich Corporation (St. Louis, MO) unless otherwise indicated.
Cells
All procedures involving animal use were in accordance with the NIH Guide for the Care and Use of Laboratory Animals, and were approved by the University Committee on Animal
Resources. Primary striatal neurons were prepared from Sprague-Dawley rat embryos (embryonic day 18) [1] .
Preparation of rat brain mitochondria and mitochondrial subfractions
Mitochondria-enriched protein fractions and mitochondrial subfractions were prepared using differential centrifugation [3, 23] .
Fluorescence microscopy
Localization of RyR was observed in live or fixed cultured striatal neurons using confocal microscopy (Leica, Heidelberg Germany). Scatter 2D plots of pixel intensities and Pearson's correlation coefficient were obtained by Image J software (NIH) [23] . We also observed that the treatment of another RyR blocker, ryanodine, also significantly inhibited mitochondrial Ca 2+ uptake in response to the application of Ca 2+ into the extracellular solution ( Supplementary Fig.2 ). These results indicate that in neurons, RyR is involved in the mitochondrial Ca 2+ uptake mechanism.
Measurements of cytosolic and mitochondrial

RyR is expressed in the inner mitochondrial membrane in neurons
We next tested whether RyR is expressed in mitochondria (i.e. mRyR) using biochemical approaches. Using specific antibody against RyR, we confirmed that RyR was detectable in mitochondria-enriched protein fractionation obtained from whole brain ( Fig.2A and B) . Because
RyR is mainly expressed in SR/ER, the purity of our mitochondria-enriched protein fractionation was evaluated by detection of voltage-dependent anion channel (VDAC) and calnexin by
Western blotting as mitochondrial and ER/SR markers, respectively [3] . The mitochondriaenriched protein fractionation obtained from whole brain showed that RyR is found in both in cytosolic (including SR)-and mitochondria-enriched protein fraction (Fig.1B) . To determine the submitochondrial localization of RyR in brain mitochondria, the IMM-enriched proteins were separated by osmotic shock from the outer mitochondrial membrane (OMM) and the contact site (CS) fractions. Separation of OMM-, CS-, and IMM-enriched fractions was confirmed by the detection of the levels of marker proteins for IMM and OMM, adenine-nucleotide translocator (ANT) and VDAC, respectively (Fig.2B) . RyR was detectable mainly from IMM, which is similar to the results we reported in cardiomyocytes [3] .
Expression of RyR in mitochondria was further confirmed in cultured live striatal neurons.
First, we labeled RyR with fluorescence-dye (Bodipy) conjugated ryanodine (Bodipy-Ry) in live cultured striatal neurons (Fig.2C) . Bodipy-Ry showed a mesh-like staining pattern with punctuate staining region. We also found that punctuate staining regions of Bodipy-Ry were colocalized with MTR staining, suggesting that RyR is partially expressed in mitochondria. Timelapse imaging showed that these spots moved, which further verified that this punctuate structures were indeed mitochondria ( Supplementary Fig.3 ). For comparison, we also stained the neuron cells with Bodipy-Thap for labeling ER. The Bodipy-Thap signals showed almost no colocalization with MTR (Fig.2C) . Scatter 2D plots of pixel intensities in red (MTR) and green (Bodipys) channels indicated that the cells stained by Bodipy-Ry possessed higher amount of co-localized pixels (yellow in segment 3 in Fig.2C ) compared to those observed in the cells stained by Bodipy-Thap. We next quantitatively assessed an efficiency of the mitochondrial colocalization by calculating the values of Pearson's correlation [23] (Fig.2C) . The Pearson's value for Bodipy-Ry-MTR staining was higher than that in Bodipy-Thap-MTR staining (0.716 vs 0.322 in Fig.2C ), suggesting that RyR was not only localized at ER, but also partially localized at mitochondria. In contrast to neurons, no colocalization of the Bodipy-Ry and MTR was observed in glia cells ( Supplementary Fig.4 ) (Pearson's value=0.276). In addition, red-range Bodipy-Ry (Bodipy-TR-Ry) was almost colocalized with Bodipy-Thap, suggesting that RyR is expressed in ER, but not in mitochondria in glia cells (Pearson's value=0.828).
Expression of RyR in mitochondria was further confirmed by immunocytochemistry using the same RyR-specific antibody used in Western blotting (Fig.2D , see also Fig.2A and B) .
Confocal analysis revealed a mesh-like staining pattern with punctuate staining region for RyR. Double labeling against Cox (an IMM protein) confirmed that RyR partially localized at mitochondrial localization (see fluorescence profiles in Fig.2D ).
Characterization of mRyR in brain mitochondria
Finally, we further characterized the neuronal mRyR using [ 3 H]ryanodine binding assays (Fig.3) . (Fig.3A) . 
Discussion
In the present study, we report the molecular and functional identification of mRyR in neuron.
First, we showed in cultured primary cells that neuronal mitochondrial Ca 2+ accumulation is sensitive to both ryanodine and dantrolene ( Fig.1 and Supplementary Fig.2 ). Second, using brain mitochondria and cultured primary cells, we found that RyR is not only expressed in ER, but also in mitochondria possibly at IMM (Fig.2) . Third, we characterized neuronal mRyR and found that the properties of ryanodine binding are similar to those we observed in cardiac mRyR [3] (Fig.3) . These results indicate that, in addition to MCU, RyR is involved in the mitochondrial Ca 2+ influx mechanism in neurons, similar to our previous observation in another excitable celltype, cardiomyocytes [3] .
Our finding that neurons express mRyR adds a new component to the complexity of mitochondrial Ca 2+ uptake in neuron. The prevailing view is that the ruthenium red-inhibitive MCU is exclusively responsible for mitochondrial Ca 2+ influx (see review [19] ). However, the growing evidence also advances the idea that multiple Ca 2+ influx mechanisms coexist, including our findings of mRyR [24, 25] . Indeed, we showed that ryanodine or dantrolene treatment significantly inhibited the mitochondrial Ca 2+ accumulation in neuron, but did not completely abolish, suggesting that other ion channel/transporters are engaged in mitochondrial Ca 2+ mechanism and mRyR serves as a part of this mechanism ( Fig.1 and Supplementary   Fig.2) . Elucidation of the unique biophysical characteristics and physiological functions for each Ca 2+ influx mechanism is significant for our understanding of mitochondrial Ca 2+ signaling in regulating physiology and pathophysiology in excitable cells including neurons. Recent studies revealed that dantrolene treatment is significantly protective from cytotoxicity in neurons and/or the progression of neurodegenerative disorders [5, 14, 22] , suggesting the potential importance of RyR in neuronal cell death signaling under the pathophysiological conditions. Future studies will address our next hypothesis: mRyR in neurons is involved in the regulation of ATP production through Ca 2+ accumulation, as we previously showed in the heart, [3, 23] and how mRyR expression levels and functions might be altered under pathophysiological conditions. In brain, all three RyR subtypes (RyR1, 2 and 3) are expressed [9, 11, 27, 31] . However, in our biochemical and cell biological studies (Figs.2&3) , we used RyR-isoform non-specific antibody and Bodipy-Ry to identify mRyR in neuronal cells, which could not distinguish which isoform(s) is (are) expressed in mitochondria. We previously reported that RyR2 is expressed at SR and RyR1 can be expressed only in mitochondria, but not in SR in cardiac cells, suggesting that the molecular identity of mRyR in cardiomyocytes is RyR1 [3, 23] . RyR2 is not only expressed in SR/ER, but also at the plasma membrane [20] or in the Golgi complex [6] , which supports our idea of RyR isoform-dependent subcellular distribution/retention. Thus, it is a reasonable idea that multiple RyR subtypes are expressed in a single neuronal cell and each isoform has a different subcellular localization as shown in cardiomyocytes. Further studies will be required to precisely identify the isoform(s) of mRyR in neuron (whether neuronal mRyR is RyR1 or not) using genetic knockdown or overexpression as we performed in cardiac cells [3, 23] .
In addition, RyR subtypes show different spatial and temporal expression patterns among various brain regions [9, 11, 27, 31] . The main RyR isoform is RyR2 [15, 17, 18] , which is evenly expressed throughout the brain at relatively high levels. RyR3 is also ubiquitously expressed in the brain at lower levels compared to RyR2 [9, 11, 31] and serves as a part of the Ca 2+ -release mechanism in ER [21, 29] . Interestingly, skeletal-muscle type isoform RyR1 is expressed in the brain [11, 31] , particularly at the cerebellum, cortex, and hippocampus [16, 30] , but the physiological relevance of the uneven distribution pattern of RyR1 is completely unknown. The brain is an organ with a high metabolic demand and energy availability determines the power and speed of the neuronal transmission system. Since the cerebellum, cortex, and hippocampus have a high number of synapses [28] and use ATP to accelerate synaptic transmission, act as a neurotransmitter [4] , generate action potential, and maintain resting potentials [13] : it is a feasible idea that the neuronal cells in these regions possess an additional molecular mechanism to enhance the efficiency of Ca 2+ -dependent ATP production in mitochondria (mRyR), similar to cardiomyocytes. Further studies will address the different expression levels of mRyR between various brain regions and also will clarify whether the mRyR expression pattern in the brain has a correlation to the mitochondrial bioenergetics and cellular energy demands in the central nervous system.
Conclusion
Our studies show the molecular and functional identification of mRyR in neuronal mitochondria. Our results suggest that mRyR may function to sequester Ca 
